Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform
Sadman Bhuiyan
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Search for more papers by this authorMatthew Shen
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Search for more papers by this authorSharenya Chelvaretnam
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Search for more papers by this authorAndre Y. Tan
HistoIndex Pte Ltd, The LaunchPad, Fusionopolis, Singapore
Search for more papers by this authorGideon Ho
HistoIndex Pte Ltd, The LaunchPad, Fusionopolis, Singapore
Search for more papers by this authorMohammed Akhter Hossain
Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorCorresponding Author
Robert E. Widdop
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Correspondence
Robert E. Widdop and Chrishan S. Samuel, Department of Pharmacology, Monash University, Clayton, Melbourne, VIC 3800, Australia.
Email: [email protected] (R.E. W.); [email protected] (C.S. S.)
Search for more papers by this authorCorresponding Author
Chrishan S. Samuel
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Department of Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, VIC, Australia
Correspondence
Robert E. Widdop and Chrishan S. Samuel, Department of Pharmacology, Monash University, Clayton, Melbourne, VIC 3800, Australia.
Email: [email protected] (R.E. W.); [email protected] (C.S. S.)
Search for more papers by this authorSadman Bhuiyan
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Search for more papers by this authorMatthew Shen
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Search for more papers by this authorSharenya Chelvaretnam
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Search for more papers by this authorAndre Y. Tan
HistoIndex Pte Ltd, The LaunchPad, Fusionopolis, Singapore
Search for more papers by this authorGideon Ho
HistoIndex Pte Ltd, The LaunchPad, Fusionopolis, Singapore
Search for more papers by this authorMohammed Akhter Hossain
Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorCorresponding Author
Robert E. Widdop
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Correspondence
Robert E. Widdop and Chrishan S. Samuel, Department of Pharmacology, Monash University, Clayton, Melbourne, VIC 3800, Australia.
Email: [email protected] (R.E. W.); [email protected] (C.S. S.)
Search for more papers by this authorCorresponding Author
Chrishan S. Samuel
Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Melbourne, VIC, Australia
Department of Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, VIC, Australia
Correspondence
Robert E. Widdop and Chrishan S. Samuel, Department of Pharmacology, Monash University, Clayton, Melbourne, VIC 3800, Australia.
Email: [email protected] (R.E. W.); [email protected] (C.S. S.)
Search for more papers by this authorAbstract
Current histological measurement techniques for interstitial collagen, the basis of interstitial fibrosis, are semi-quantitative at best and only provide a ratio of collagen levels within tissues. The Genesis200 imaging system and supplemental image analysis software, FibroIndex from HistoIndex, is a novel, automated platform that uses second-harmonic generation (SHG) for imaging and characterization of interstitial collagen deposition and additional characteristics, in the absence of any staining. However, its ability to quantify renal fibrosis requires investigation. This study compared SHG imaging of renal fibrosis in mice with unilateral ureteric obstruction (UUO), to that of Masson’s trichrome staining (MTS) and immunohistochemistry (IHC) of collagen I. Additionally, the platform generated data on collagen morphology and distribution patterns. While all three methods determined that UUO-injured mice underwent significantly increased renal fibrosis after 7 days, the HistoIndex platform additionally determined that UUO-injured mice had a significantly increased collagen-to-tissue cross reticulation ratio (all P < .001 vs sham group). Furthermore, in UUO-injured mice treated with the relaxin family peptide receptor-1 agonists, relaxin (0.5 mg/kg/day) or B7-33 (0.25 mg/kg/day), or angiotensin converting enzyme-inhibitor, perindopril (1 mg/kg/day) over the 7-day period, only the HistoIndex platform determined that the drug-induced prevention of renal fibrosis correlated with significantly reduced collagen fiber thickness and collagen-to-tissue cross reticulation ratio, but increased collagen fiber counts. Relaxin or B7-33 treatment also increased renal matrix metalloproteinase-2 and reduced tissue inhibitor of metalloproteinase-1 levels (all P < .01 vs UUO alone). This study demonstrated the diagnostic value of the HistoIndex platform over currently used staining techniques.
CONFLICTS OF INTEREST
All other authors declare no conflicts of interest.
REFERENCES
- 1Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol. 2009; 296: F1239-F1244.
- 2Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogen Tiss Rep. 2014; 7: 4.
- 3Boutaud A, Borza DB, Bondar O, et al. Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous nc1 domains. J Biol Chem. 2000; 275: 30716-30724.
- 4Meran S, Steadman R. Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol. 2011; 92: 158-167.
- 5LeBleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19: 1047-1053.
- 6Zhou D, Liu Y. Renal fibrosis in 2015: understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol. 2016; 12: 68-70.
- 7Farris AB, Alpers CE. What is the best way to measure renal fibrosis? a pathologist’s perspective. Kidney Int Suppl. 2014; 4: 9-15.
- 8Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem. 1963; 35: 1961-1965.
- 9Samuel CS. Determination of collagen content, concentration, and sub-types in kidney tissue. Methods Mol Biol. 2009; 466: 223-235.
- 10Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003; 9: 796-800.
- 11Hora H. The principles of nonlinear optics. In: YR Shen, ed. Laser Particle Beams. New York, NY: John Wiley and Sons; 1984:576 p.
- 12Tran RJ, Sly KL, Conboy JC. Applications of surface second harmonic generation in biological sensing. Ann Rev Anal Chem. 2017; 10: 387-414.
- 13Xu S, Kang CH, Gou X, et al. Quantification of liver fibrosis via second harmonic imaging of the glisson's capsule from liver surface. J Biophotonics. 2016; 9: 351-363.
- 14Wang BG, Eitner A, Lindenau J, Halbhuber KJ. High-resolution two-photon excitation microscopy of ocular tissues in porcine eye. Lasers Surg Med. 2008; 40: 247-256.
- 15Williams RM, Zipfel WR, Webb WW. Interpreting second-harmonic generation images of collagen I fibrils. Biophys J. 2005; 88: 1377-1386.
- 16Freund I, Deutsch M, Sprecher A. Connective tissue polarity. Optical second-harmonic microscopy, crossed-beam summation, and small-angle scattering in rat-tail tendon. Biophys J. 1986; 50: 693-712.
- 17Fine S, Hansen WP. Optical second harmonic generation in biological systems. Appl Opt. 1971; 10: 2350-2353.
- 18Chen X, Nadiarynkh O, Plotnikov S, Campagnola PJ. Second harmonic generation microscopy for quantitative analysis of collagen fibrillar structure. Nat Protoc. 2012; 7: 654-669.
- 19Zoumi A, Yeh A, Tromberg BJ. Imaging cells and extracellular matrix in vivo by using second-harmonic generation and two-photon excited fluorescence. Proc Natl Acad Sci USA. 2002; 99: 11014-11019.
- 20Lattouf R, Younes R, Lutomski D, et al. Picrosirius red staining: a useful tool to appraise collagen networks in normal and pathological tissues. J Histochem Cytochem. 2014; 62: 751-758.
- 21Wang TH, Chen TC, Teng X, Liang KH, Yeh CT. Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy. Sci Rep. 2015; 5: 12962.
- 22Diamond JR, Ricardo SD, Klahr S. Mechanisms of interstitial fibrosis in obstructive nephropathy. Sem Nephrol. 1998; 18: 594-602.
- 23Martinez-Klimova E, Aparicio-Trejo OE, Tapia E, Pedraza-Chaverri J Unilateral ureteral obstruction as a model to investigate fibrosis-attenuating treatments. Biomolecules. 2019; 9: 141.
- 24Hewitson TD, Ho WY, Samuel CS. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology. 2010; 151: 4938-4948.
- 25Huuskes BM, Wise AF, Cox AJ, et al. Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy. FASEB J. 2015; 29: 540-553.
- 26Wetzl V, Schinner E, Kees F, Hofmann F, Faerber L, Schlossmann J. Involvement of cyclic guanosine monophosphate-dependent protein kinase I in renal antifibrotic effects of serelaxin. Front Pharmacol. 2016; 7: 195.
- 27Hossain MA, Kocan M, Yao ST, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the g protein-coupled receptor, rxfp1. Chem Sci. 2016; 7: 3805-3819.
- 28Unger T, Moursi M, Ganten D, Hermann K, Lang RE. Antihypertensive action of the converting enzyme inhibitor perindopril (s9490-3) in spontaneously hypertensive rats: comparison with enalapril (mk421) and ramipril (hoe498). J Cardiovasc Pharmacol. 1986; 8: 276-285.
- 29Nagai M, Horikoshi K, Izumi T, et al. Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Therapy. 2004; 18: 353-362.
- 30Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology. 2004; 145: 4125-4133.
- 31Samuel CS, Zhao C, Yang Q, et al. The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol. 2005; 125: 692-699.
- 32Paull JR, Widdop RE. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. J Hypertens. 2001; 19: 1393-1402.
- 33Chow BSM, Kocan M, Shen M, et al. AT1R-AT2R-RXFP1 functional crosstalk in myofibroblasts: Impact on the therapeutic targeting of renal and cardiac fibrosis. J Am Soc Nephrology. 2019; 30: 2191-2207.
- 34Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009; 75: 1145-1152.
- 35Becker GJ, Hewitson TD. The interstitium in renal disease. J Intern Med. 1997; 242: 93-97.
- 36Blacker TS, Duchen MR. Investigating mitochondrial redox state using NADH and NADPH autofluorescence. Free Rad Biol Med. 2016; 100: 53-65.
- 37Alexakis C, Maxwell P, Bou-Gharios G. Organ-specific collagen expression: Implications for renal disease. Nephron Exp Nephrol. 2006; 102: e71-e75.
- 38Hara S, Kawano M, Mizushima I, et al. Distribution and components of interstitial inflammation and fibrosis in igg4-related kidney disease: analysis of autopsy specimens. Hum Pathol. 2016; 55: 164-173.
- 39Chang PE, Goh GB, Leow WQ, Shen L, Lim KH, Tan CK. Second harmonic generation microscopy provides accurate auotmated staging of liver fibrosis in patients with non-alcoholic fatty liver disease. PLoS ONE. 2018; 13:e0199166.
- 40Oostendorp C, Uijtdewilligen PJE, Versteeg EM, et al. Visualisation of newly synthesised collagen in vitro and in vivo. Sci Rep. 2016; 6: 18780.
- 41Tatsukawa H, Otsu R, Tani Y, Wakita R, Hitomi K. Isozyme-specifc comprehensive characterization of transglutaminase-crosslinked substrates in kidney fbrosis. Sci Rep. 2018; 8: 7306.
- 42Garber SL, Mirochnik Y, Brecklin CS, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001; 59: 876-882.
- 43Bennett RG. Relaxin and its role in the development and treatment of fibrosis. Trans Res. 2009; 154: 1-6.
- 44Yoshida T, Kumagai H, Suzuki A, et al. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis. Nephrol Dial Transpl. 2012; 27: 2190-2197.
- 45Collino M, Rogazzo M, Pini A, et al. Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. J Cell Mol Med. 2012; 17: 1494-1505.
- 46Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem. 1990; 265: 10661-10665.
- 47Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996; 98: 2739-2745.
- 48Liu F, Wei CC, Wu SJ, et al. Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int. 2009; 75: 156-166.
- 49Kelly DJ, Zhang Y, Cox AJ, Gilbert RE. Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int. 2006; 69: 1954-1960.